Eunice Wang, MD

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.

Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.

Bijal Shah, MD, MS, and Eunice Wang, MD, discuss efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and review key safety data.

Eunice Wang, MD, and Bijal Shah, MD, MS, discuss the overall study design and patient population of the ZUMA-3 trial of CAR T-cell therapy in adult patients with R/R ALL.

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.  

Eunice Wang, MD and Bijal Shah, MD, MS, discuss novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.